Life and death by death receptors

FASEB Journal

Volumn 23, Issue 6, 2009, Pages 1625-1637

  Guicciardi, Maria Eugenia ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bcl 2 family; Caspases; Fas CD95 APO1; MAP kinases; TNF; TRAIL

Indexed keywords

ADAPTOR PROTEIN; CASPASE 10; CASPASE 8; CHEMOKINE; DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; INFLAMMATION; INTERNALIZATION; LIGAND BINDING; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; APOPTOSIS; GENETICS; METABOLISM; PHYSIOLOGY;

ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649386107     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.08-111005     Document Type: Review

References (144)

1. Nagata, S. (1997) Apoptosis by death factor. Cell 88, 355-365
2. Ashkenazi, A., and Dixit, V. M. (1998) Death receptors: signaling and modulation. Science 281, 1305-1308
3. Locksley, R. M., Killeen, N., and Lenardo, M. J. (2001) The TNF and TNF receptor superfamily: integrating mammalian biology. Cell 104, 487-501 (Pubitemid 32201945)
4. Wajant, H. (2003) Death receptors. Essays Biochem. 39, 53-71
5. Schneider, P., Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213
6. Shudo, K., Kinoshita, K., Imamura, R., Fan, H., Hasumoto, K., Tanaka, M., Nagata, S., and Suda, T. (2001) The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur. J. Immunol. 31, 2504-2511
7. Wajant, H., Moosmayer, D., Wuest, T., Bartke, T., Gerlach, E., Schonherr, U., Peters, N., Scheurich, P., and Pfizenmaier, K. (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20, 4101-4106 (Pubitemid 32681615)
8. Grell, M., Wajant, H., Zimmermann, G., and Scheurich, P. (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. U. S. A. 95, 570-575
9. Boldin, M. P., Mett, I. L., Varfolomeev, E. E., Chumakov, I., Shemer-Avni, Y., Camonis, J. H., and Wallach, D. (1995) Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem. 270, 387-391
10. Chan, K. F., Siegel, M. R., and Lenardo, J. M. (2000) Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13, 419-422 (Pubitemid 30951865)
11. Chan, F. K., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., and Lenardo, M. J. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354 (Pubitemid 30448156)
12. Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., and Chan, F. K. (2005) Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 102, 18099-18104
13. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y., and Lenardo, M. J. (2000) Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357 (Pubitemid 30448157)
14. Salvesen, G. S., and Dixit, V. M. (1999) Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. U. S. A. 96, 10964-10967
15. Shi, Y. (2004) Caspase activation: revisiting the induced proximity model. Cell 117, 855-858
16. Chao, Y., Shiozaki, E. N., Srinivasula, S. M., Rigotti, D. J., Fairman, R., and Shi, Y. (2005) Engineering a dimeric caspase-9: a re-evaluation of the induced proximity model for caspase activation. [Online] PLoS Biol. 3, e183
17. Tschopp, J., Irmler, M., and Thome, M. (1998) Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 10, 552-558
18. Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., and Lavrik, I. N. (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 280, 14507-14513
19. Chang, D. W., Xing, Z., Pan, Y., Algeciras-Schimnich, A., Barnhart, B. C., Yaish-Ohad, S., Peter, M. E., and Yang, X. (2002) c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21, 3704-3714
20. Rasper, D. M., Vaillancourt, J. P., Hadano, S., Houtzager, V. M., Seiden, I., Keen, S. L., Tawa, P., Xanthoudakis, S., Nasir, J., Martindale, D., Koop, B. F., Peterson, E. P., Thornberry, N. A., Huang, J., MacPherson, D. P., Black, S. C., Hornung, F., Lenardo, M. J., Hayden, M. R., Roy, S., and Nicholson, D. W. (1998) Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ. 5, 271-288 (Pubitemid 28356540)
21. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (Pubitemid 27297457)
22. Krueger, A., Baumann, S., Krammer, P. H., and Kirchhoff, S. (2001) FLICE-inhibitory proteins: regulators of death receptor- mediated apoptosis. Mol. Cell. Biol. 21, 8247-8254
23. Hu, W. H., Johnson, H., and Shu, H. B. (2000) Activation of NF-κB by FADD, Casper, and Caspase-8. J. Biol. Chem. 275, 10838-10844
24. Kataoka, T., Budd, R. C., Holler, N., Thome, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M., and Tschopp, J. (2000) The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 10, 640-648
25. Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., and Grutter, M. G. (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277, 45162-45171
26. Dohrman, A., Russell, J. Q., Cuenin, S., Fortner, K., Tschopp, J., and Budd, R. C. (2005) Cellular FLIP long form augments caspase activity and death of T cells through heterodimerization with and activation of caspase-8. J. Immunol. 175, 311-318 (Pubitemid 40884333)
27. Yeh, W. C., Itie, A., Elia, A. J., Ng, M., Shu, H. B., Wakeham, A., Mirtsos, C., Suzuki, N., Bonnard, M., Goeddel, D. V., and Mak, T. W. (2000) Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12, 633-642
28. Yeh, W. C., Pompa, J. L., McCurrach, M. E., Shu, H. B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell, K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T. W. (1998) FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954-1958 (Pubitemid 28168653)
29. Peter, M. E., and Krammer, P. H. (2003) The CD95(APO-1/ Fas) DISC and beyond. Cell Death Differ. 10, 26-35
30. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (Pubitemid 28391865)
31. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (Pubitemid 28391864)
32. Milhas, D., Cuvillier, O., Therville, N., Clave, P., Thomsen, M., Levade, T., Benoist, H., and Segui, B. (2005) Caspase-10 triggers Bid cleavage and caspase cascade activation in FasL-induced apoptosis. J. Biol. Chem. 280, 19836-19842
33. Korsmeyer, S. J., Wei, M. C., Saito, M., Weiler, S., Oh, K. J., and Schlesinger, P. H. (2000) Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7, 1166-1173 (Pubitemid 32042223)
34. Meylan, E., and Tschopp, J. (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 30, 151-159
35. Ea, C. K., Deng, L., Xia, Z. P., Pineda, G., and Chen, Z. J. (2006) Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell. 22, 245-257
36. Devin, A., Lin, Y., and Liu, Z. G. (2003) The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep. 4, 623-627 (Pubitemid 36939955)
37. Lee, T. H., Shank, J., Cusson, N., and Kelliher, M. A. (2004) The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IκB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J. Biol. Chem. 279, 33185-33191
38. O'Donnell, M. A., Legarda-Addison, D., Skountzos, P., Yeh, W. C., and Ting, A. T. (2007) Ubiquitination of RIP1 regulates an NF-κB-independent cell-death switch in TNF signaling. Curr. Biol. 17, 418-424
39. Lin, Y., Devin, A., Rodriguez, Y., and Liu, Z. G. (1999) Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13, 2514-2526 (Pubitemid 29489643)
40. Festjens, N., Vanden Berghe, T., Cornelis, S., and Vandenabeele, P. (2007) RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 14, 400-410 (Pubitemid 46259948)
41. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., and Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489-495
42. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. (1995) Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154, 2706-2713
43. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759-1762 (Pubitemid 24131584)
44. Chakrabandhu, K., Herincs, Z., Huault, S., Dost, B., Peng, L., Conchonaud, F., Marguet, D., He, H. T., and Hueber, A. O. (2007) Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 26, 209-220 (Pubitemid 46094712)
45. Feig, C., Tchikov, V., Schutze, S., and Peter, M. E. (2007) Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26, 221-231 (Pubitemid 46094713)
46. Henkler, F., Behrle, E., Dennehy, K. M., Wicovsky, A., Peters, N., Warnke, C., Pfizenmaier, K., and Wajant, H. (2005) The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell Biol. 168, 1087-1098 (Pubitemid 40491178)
47. Siegel, R. M., Muppidi, J. R., Sarker, M., Lobito, A., Jen, M., Martin, D., Straus, S. E., and Lenardo, M. J. (2004) SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167, 735-744 (Pubitemid 39565153)
48. Legembre, P., Daburon, S., Moreau, P., Moreau, J. F., and Taupin, J. L. (2006) Modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes. J. Immunol. 176, 716-720 (Pubitemid 43099665)
49. Algeciras-Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., and Peter, M. E. (2002) Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22, 207-220
50. Eramo, A., Sargiacomo, M., Ricci-Vitiani, L., Todaro, M., Stassi, G., Messina, C. G., Parolini, I., Lotti, F., Sette, G., Peschle, C., and De Maria, R. (2004) CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol. 34, 1930-1940
51. Lee, K. H., Feig, C., Tchikov, V., Schickel, R., Hallas, C., Schutze, S., Peter, M. E., and Chan, A. C. (2006) The role of receptor internalization in CD95 signaling. EMBO J. 25, 1009-1023 (Pubitemid 43372115)
52. Lavrik, I. N., Mock, T., Golks, A., Hoffmann, J. C., Baumann, S., and Krammer, P. H. (2008) CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J. Biol. Chem. 283, 26401-26408
53. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (Pubitemid 28119121)
54. Barnhart, B. C., Alappat, E. C., and Peter, M. E. (2003) The CD95 type I/type II model. Semin. Immunol. 15, 185-193
55. Algeciras-Schimnich, A., and Peter, M. E. (2003) Actin dependent CD95 internalization is specific for Type I cells. FEBS Lett. 546, 185-188 (Pubitemid 36782408)
56. Hueber, A. O., Bernard, A. M., Herincs, Z., Couzinet, A., and He, H. T. (2002) An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep. 3, 190-196 (Pubitemid 34213499)
57. Scaffidi, C., Schmitz, I., Zha, J., Korsmeyer, S. J., Krammer, P. H., and Peter, M. E. (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274, 22532-22538
58. Barnhart, B. C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., and Peter, M. E. (2004) CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 23, 3175-3185 (Pubitemid 39093611)
59. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Nonapoptotic Fas signaling. Cytokine Growth Factor Rev. 14, 53-66
60. Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J. S., and Newell, M. K. (2003) Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5, 118-125
61. Reinehr, R., Sommerfeld, A., and Haussinger, D. (2008) CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 134, 1494-1506 (Pubitemid 351615364)
62. Desbarats, J., and Newell, M. K. (2000) Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6, 920-923
63. Hong, F., Nguyen, V. A., Shen, X., Kunos, G., and Gao, B. (2000) Rapid activation of protein kinase B/Akt has a key role in antiapoptotic signaling during liver regeneration. Biochem. Biophys. Res. Commun. 279, 974-979
64. Jackson, L. N., Larson, S. D., Silva, S. R., Rychahou, P. G., Chen, L. A., Qiu, S., Rajaraman, S., and Evers, B. M. (2008) PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am. J. Physiol. Gastrointest Liver Physiol. 294, G1401-G1410
65. Taub, R. (1996) Liver regeneration 4: transcriptional control of liver regeneration. FASEB J. 10, 413-427
66. Tzung, S. P., Fausto, N., and Hockenbery, D. M. (1997) Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am. J. Pathol. 150, 1985-1995
67. Kennedy, N. J., Kataoka, T., Tschopp, J., and Budd, R. C. (1999) Caspase activation is required for T cell proliferation. J. Exp. Med. 190, 1891-1896
68. Newton, K., Harris, A. W., Bath, M. L., Smith, K. G., and Strasser, A. (1998) A dominant interfering mutant of FADD/ MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17, 706-718 (Pubitemid 28062050)
69. Muschen, M., Warskulat, U., and Beckmann, M. W. (2000) Defining CD95 as a tumor suppressor gene. J. Mol. Med. 78, 312-325
70. Straus, S. E., Jaffe, E. S., Puck, J. M., Dale, J. K., Elkon, K. B., Rosen-Wolff, A., Peters, A. M., Sneller, M. C., Hallahan, C. W., Wang, J., Fischer, R. E., Jackson, C. M., Lin, A. Y., Baumler, C., Siegert, E., Marx, A., Vaishnaw, A. K., Grodzicky, T., Fleisher, T. A., and Lenardo, M. J. (2001) The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194-200
71. Legembre, P., Barnhart, B. C., and Peter, M. E. (2004) The relevance of NF-κB for CD95 signaling in tumor cells. Cell Cycle 3, 1235-1239 (Pubitemid 40268600)
72. Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., Schreglmann, N., Letellier, E., Zuliani, C., Klussmann, S., Teodorczyk, M., Grone, H. J., Ganten, T. M., Sultmann, H., Tuttenberg, J., von Deimling, A., Regnier-Vigouroux, A., Herold-Mende, C., and Martin-Villalba, A. (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13, 235-248 (Pubitemid 351324880)
73. Peter, M. E., Legembre, P., and Barnhart, B. C. (2005) Does CD95 have tumor promoting activities? Biochim. Biophys. Acta 1755, 25-36
74. Legembre, P., Barnhart, B. C., Zheng, L., Vijayan, S., Straus, S. E., Puck, J., Dale, J. K., Lenardo, M., and Peter, M. E. (2004) Induction of apoptosis and activation of NF-κB by CD95 require different signalling thresholds. EMBO Rep. 5, 1084-1089 (Pubitemid 39600208)
75. Chakrabandhu, K., Huault, S., Garmy, N., Fantini, J., Stebe, E., Mailfert, S., Marguet, D., and Hueber, A. O. (2008) The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ. 15, 1824-1837
76. Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (Pubitemid 27366732)
77. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997) The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113
78. Golstein, P. (1997) Cell death: TRAIL and its receptors. Curr. Biol. 7, R750-R753
79. Grosse-Wilde, A., Voloshanenko, O., Bailey, S. L., Longton, G. M., Schaefer, U., Csernok, A. I., Schutz, G., Greiner, E. F., Kemp, C. J., and Walczak, H. (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 118, 100-110
80. Grosse-Wilde, A., and Kemp, C. J. (2008) Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res. 68, 6035-6037
81. Finnberg, N., Klein-Szanto, A. J., and El-Deiry, W. S. (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111-123
82. Schaefer, U., Voloshanenko, O., Willen, D., and Walczak, H. (2007) TRAIL: a multifunctional cytokine. Front. Biosci. 12, 3813-3824
83. Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C. P., DuBose, R. F., Goodwin, R. G., and Smith, C. A. (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165-1170
84. Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. (1997) The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813-820
85. Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., Foa, R., Lo Coco, F., Peschle, C., and Testa, U. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90, 612-624 (Pubitemid 40780880)
86. Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O. (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 26, 7046-7055
87. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V., and Doyle, M. L. (2000) Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319-23325
88. Mariani, S. M., and Krammer, P. H. (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28, 973-982
89. Bodmer, J. L., Meier, P., Tschopp, J., and Schneider, P. (2000) Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275, 20632-20637
90. Trabzuni, D., Famulski, K. S., and Ahmad, M. (2000) Functional analysis of tumour necrosis factor-alpha-related apoptosis- inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem. J. 350, 505-510 (Pubitemid 30708418)
91. Hayakawa, Y., Screpanti, V., Yagita, H., Grandien, A., Ljunggren, H. G., Smyth, M. J., and Chambers, B. J. (2004) NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 172, 123-129 (Pubitemid 38020463)
92. Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., and Schoenberger, S. P. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93
93. Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R., and Yagita, H. (2003) Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18, 1-6 (Pubitemid 36120682)
94. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (Pubitemid 26091143)
95. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690
96. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162
97. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7, 383-385
98. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med. 5, 157-163
99. Gores, G. J., and Kaufmann, S. H. (2001) Is TRAIL hepatotoxic? Hepatology 34, 3-6
100. Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Buchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., and Walczak, H. (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. 12, 2640-2646
101. Ashkenazi, A., and Herbst, R. S. (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118, 1979-1990
102. Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., Deforge, L., Pai, R., Hymowitz, S. G., and Ashkenazi, A. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280, 2205-2212
103. Kuang, A. A., Diehl, G. E., Zhang, J., and Winoto, A. (2000) FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275, 25065-25068
104. Kohlhaas, S. L., Craxton, A., Sun, X. M., Pinkoski, M. J., and Cohen, G. M. (2007) Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282, 12831-12841
105. Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., Huw, L., Katta, V., Cavet, G., Hymowitz, S. G., Amler, L., and Ashkenazi, A. (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13, 1070-1077
106. Falschlehner, C., Emmerich, C. H., Gerlach, B., and Walczak, H. (2007) TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39, 1462-1475
107. Hu, W. H., Johnson, H., and Shu, H. B. (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274, 30603-30610
108. Kim, Y. S., Schwabe, R. F., Qian, T., Lemasters, J. J., and Brenner, D. A. (2002) TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36, 1498-1508 (Pubitemid 35403540)
109. Varfolomeev, E., Maecker, H., Sharp, D., Lawrence, D., Renz, M., Vucic, D., and Ashkenazi, A. (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280, 40599-40608
110. Petersen, S. L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., Harran, P., and Wang, X. (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic- induced apoptosis. Cancer Cell 12, 445-456 (Pubitemid 350064365)
111. Soderstrom, T. S., Poukkula, M., Holmstrom, T. H., Heiskanen, K. M., and Eriksson, J. E. (2002) Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169, 2851-2860 (Pubitemid 35013125)
112. Tran, S. E., Holmstrom, T. H., Ahonen, M., Kahari, V. M., and Eriksson, J. E. (2001) MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276, 16484-16490
113. Lee, T. J., Lee, J. T., Park, J. W., and Kwon, T. K. (2006) Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351, 1024-1030
114. Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., and Gores, G. J. (2007) cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1337-G1346
115. Ishimura, N., Isomoto, H., Bronk, S. F., and Gores, G. J. (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G129-G136
116. Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Roder, C., Kalthoff, H., and Wajant, H. (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25, 7434-7439 (Pubitemid 44853434)
117. Leverkus, M., Sprick, M. R., Wachter, T., Denk, A., Brocker, E. B., Walczak, H., and Neumann, M. (2003) TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J. Invest. Dermatol. 121, 149-155
118. Inoue, H., Shiraki, K., Yamanaka, T., Ohmori, S., Sakai, T., Deguchi, M., Okano, H., Murata, K., Sugimoto, K., and Nakano, T. (2002) Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab. Invest. 82, 1111-1119
119. Secchiero, P., Gonelli, A., Carnevale, E., Corallini, F., Rizzardi, C., Zacchigna, S., Melato, M., and Zauli, G. (2004) Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6, 364-373 (Pubitemid 38924851)
120. Koyama, S., Koike, N., and Adachi, S. (2002) Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 128, 73-79
121. Zhao, S., Asgary, Z., Wang, Y., Goodwin, R., Andreeff, M., and Younes, A. (1999) Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br. J. Haematol. 106, 827-832
122. Rieger, J., Ohgaki, H., Kleihues, P., and Weller, M. (1999) Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol. 97, 1-4 (Pubitemid 29132639)
123. Frank, S., Kohler, U., Schackert, G., and Schackert, H. K. (1999) Expression of TRAIL and its receptors in human brain tumors. Biochem. Biophys. Res. Commun. 257, 454-459
124. Lancaster, J. M., Sayer, R., Blanchette, C., Calingaert, B., Whitaker, R., Schildkraut, J., Marks, J., and Berchuck, A. (2003) High expression of tumor necrosis factor-related apoptosis- inducing ligand is associated with favorable ovarian cancer survival. Clin. Cancer Res. 9, 762-766
125. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., and Boldin, M. P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367
126. Pfeffer, K., Matsuyama, T., Kundig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Kronke, M., and Mak, T. W. (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467 (Pubitemid 23143346)
127. Zhao, Y. X., Lajoie, G., Zhang, H., Chiu, B., Payne, U., and Inman, R. D. (2000) Tumor necrosis factor receptor p55- deficient mice respond to acute Yersinia enterocolitica infection with less apoptosis and more effective host resistance. Infect. Immun. 68, 1243-1251
128. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65
129. Micheau, O., and Tschopp, J. (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190 (Pubitemid 36936912)
130. Harper, N., Hughes, M., MacFarlane, M., and Cohen, G. M. (2003) Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. J. Biol. Chem. 278, 25534-25541
131. Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., Held-Feindt, J., Heinrich, M., Merkel, O., Ehrenschwender, M., Adam, D., Mentlein, R., Kabelitz, D., and Schutze, S. (2004) Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21, 415-428 (Pubitemid 39208342)
132. Legler, D. F., Micheau, O., Doucey, M. A., Tschopp, J., and Bron, C. (2003) Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18, 655-664 (Pubitemid 36588582)
133. Li, H., Kobayashi, M., Blonska, M., You, Y., and Lin, X. (2006) Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-κB activation. J. Biol. Chem. 281, 13636-13643
134. Wajant, H., and Scheurich, P. (2001) Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int. J. Biochem. Cell Biol. 33, 19-32
135. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S. (1998) NF-κB antiapoptosis: induction of TRAF 1 and TRAF 2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683 (Pubitemid 28435585)
136. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A. (2001) Inhibition of JNK activation through NF-κB target genes. Nature 414, 313-317 (Pubitemid 33097808)
137. Chang, L., Kamata, H., Solinas, G., Luo, J. L., Maeda, S., Venuprasad, K., Liu, Y. C., and Karin, M. (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613 (Pubitemid 43199444)
138. Schneider-Brachert, W., Tchikov, V., Merkel, O., Jakob, M., Hallas, C., Kruse, M. L., Groitl, P., Lehn, A., Hildt, E., Held- Feindt, J., Dobner, T., Kabelitz, D., Kronke, M., and Schutze, S. (2006) Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J. Clin. Invest. 116, 2901-2913
139. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274, 787-789
140. Neumeyer, J., Hallas, C., Merkel, O., Winoto-Morbach, S., Jakob, M., Thon, L., Adam, D., Schneider-Brachert, W., and Schutze, S. (2006) TNF-receptor I defective in internalization allows for cell death through activation of neutral sphingomyelinase. Exp. Cell. Res. 312, 2142-2153
141. Yoshimura, S., Banno, Y., Nakashima, S., Takenaka, K., Sakai, H., Nishimura, Y., Sakai, N., Shimizu, S., Eguchi, Y., Tsujimoto, Y., and Nozawa, Y. (1998) Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation. J. Biol. Chem. 273, 6921-6927
142. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., Deshayes, K., Dixit, V. M., and Vucic, D. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681
143. Wang, L., Du, F., and Wang, X. (2008) TNF-α induces two distinct caspase-8 activation pathways. Cell 133, 693-703 (Pubitemid 351636305)
144. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell. 30, 689-700